Targeting Lipoprotein(a) — the Next Frontier in Cardiovascular Disease
Author:
- 1 May 2025
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 392 (17) , 1740-1742
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a)New England Journal of Medicine, 2025
- Lipoprotein(a) and cardiovascular diseaseBiochemical Journal, 2024
- Single Ascending and Multiple-Dose Trial of Zerlasiran, a Short Interfering RNA Targeting Lipoprotein(a)JAMA, 2024
- High lipoprotein(a): Actionable strategies for risk assessment and mitigationAmerican Journal of Preventive Cardiology, 2024
- Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a)JAMA, 2023
- Lipoprotein(a), Oxidized Phospholipids, and Coronary Artery Disease Severity and OutcomesJACC, 2023
- Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular DiseaseNew England Journal of Medicine, 2022
- Characterization of Lipoprotein(a) Measurement in a Large US Healthcare DatasetJournal of Clinical Lipidology, 2022
- Lipoprotein(a) Reduction in Persons with Cardiovascular DiseaseNew England Journal of Medicine, 2020
- Association ofLPAVariants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering TherapiesJAMA Cardiology, 2018